Skip to main content

Table 6 Results of this analysis

From: Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials

Outcomes reported

No of studies involved (n)

OR with 95% CI

P values

I2 (%)

Drug discontinuation

9

1.35 [1.06–1.72]

0.01

31

Serious AEs

7

1.01 [0.79–1.29]

0.93

0

Deaths

5

1.13 [0.43–2.94]

0.80

0

UTIs

7

0.93 [0.70–1.23]

0.61

0

P. dizziness

3

1.51 [0.42–5.37]

0.53

0

Hypoglycemia

5

0.96 [0.81–1.13]

0.60

0

Any AEs

8

1.04 [0.85–1.28]

0.72

52

  1. Abbreviations: AEs adverse events, UTIs urinary tract infections, P. dizziness postural dizziness, OR odds ratios, CI confidence intervals